Q32 Bio Inc.
QTTB evidence brief
What we can confirm
- BioSniper Score:
- 6.9 / 10
- Market Cap:
- $274.8M
- Lead Asset:
- adx-097 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for QTTB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · QTTB
Q32 Bio Inc. (QTTB) is a clinical-stage biotechnology company developing bempikibart, an anti-IL-7Rα antibody for alopecia areata and other autoimmune diseases, with a Phase 2a trial showing positive 36-week results.
Key risk: Early-stage program risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$274.8M
Cash Runway
—
Lead Asset
adx-097 (Phase 2)
Next Catalyst
—
Tracking 2 pipeline candidates · 1 clinical trial for Q32 Bio Inc..
Q32 Bio Inc. (QTTB) is a clinical-stage biotechnology company developing bempikibart, an anti-IL-7Rα antibody for alopecia areata and other autoimmune diseases, with a Phase 2a trial showing positive 36-week results.
- Lead candidate bempikibart (ADX-914) is a fully human anti-IL-7Rα antagonist monoclonal antibody in Phase 2 for alopecia areata [pipeline].
- Positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial were announced on July 13, 2026 [news · 2026-07-13].
- Additional 36-week results and initial 16-week off-drug period findings were presented at the European Academy of Dermatology and Venereology Congress in September 2026 [news · 2026-09-30].
- Bempikibart has received Fast Track regulatory status [pipeline].
- The company has a collaboration with Bristol-Myers Squibb Company including an upfront payment of $8 million and potential milestones [pipeline].
What works
- Bempikibart targets a novel mechanism (IL-7Rα blockade) that may re-regulate adaptive immune function, potentially offering a differentiated approach versus JAK inhibitors in alopecia areata [pipeline].
- The SIGNAL-AA Phase 2a trial produced positive 36-week topline results, supporting further development [news · 2026-07-13].
- Fast Track designation from the FDA may accelerate development and review [pipeline].
- A partnership with Bristol-Myers Squibb provides non-dilutive funding and development resources [pipeline].
What to weigh
- Bempikibart is still in Phase 2a; no pivotal Phase 3 data are yet available, leaving regulatory and commercial risk [pipeline].
- The alopecia areata competitive landscape includes established JAK inhibitors (baricitinib, ritlecitinib) and other therapies [pipeline].
- The company divested a non-core asset in early 2026, indicating a sharpened but narrower focus [news · 2026-03-01].
- Financial details such as cash position and accumulated deficit are not provided in the available chunks, limiting assessment of runway.
From the filings
Quoted directly from source documents.
Bempikibart is a fully human anti-IL-7Rα antibody designed to block IL-7 and TSLP signaling.
“Fully human anti-interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7) and thymic stromal lymphopoietin (TSLP).”
Bempikibart has Fast Track regulatory status.
“Regulatory Status: Fast Track”
Catalyst timeline
- 2023-09-12 · Phase 2a start of SIGNAL-AA trial for bempikibart in alopecia areata — The Phase 2a randomized, double-blind, placebo-controlled trial with Part B and open-label extension began enrollment.
Risks & what to watch (3)›
Key risks
- Early-stage program risk — Bempikibart is only in Phase 2a; no Phase 3 data exist, so regulatory and commercial outcomes are uncertain [pipeline].
- Competitive pressure in AA — Alopecia areata market includes JAK inhibitors (baricitinib, ritlecitinib) and other established therapies [pipeline].
- Narrowed corporate focus — Divestiture of a non-core asset in early 2026 may reduce diversification [news · 2026-03-01].
What to watch
- Initiation of Phase 3 trials for bempikibart in alopecia areata [pipeline].
- Any additional data from the off-drug period of the SIGNAL-AA trial [news · 2026-09-30].
- Progress of the second pipeline candidate, adx-097, in IgA Nephropathy (Phase 2) [pipeline].
- Financial updates including cash position and accumulated deficit (not yet disclosed in available chunks).
Sources: Catalysts · News · Pipeline · Generated October 9, 2026 · How we verify sources →
Run Q32 Bio Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Q32 Bio Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
4 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 7.0%
- Days to cover
- 1.3
- Shares short
- 411,011
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
QTTB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Q32 Bio Inc.?
Q32 Bio Inc. (QTTB) is a clinical-stage biotechnology company developing bempikibart, an anti-IL-7Rα antibody for alopecia areata and other autoimmune diseases, with a Phase 2a trial showing positive 36-week results.
What is Q32 Bio Inc.'s lead drug candidate?
Q32 Bio Inc.'s most advanced tracked candidate is adx-097 (Phase 2) for IgA Nephropathy.
Who is the CEO of Q32 Bio Inc.?
Ms. Jodie Pope Morrison is the chief executive officer of Q32 Bio Inc. (QTTB).
Where is Q32 Bio Inc. headquartered?
Q32 Bio Inc. (QTTB) is headquartered in Waltham, MA, United States.
What therapeutic areas does Q32 Bio Inc. focus on?
Q32 Bio Inc. develops therapies across Immunology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.